source
- Ultragenyx's Angelman syndrome drug fails in Phase 3 trial, showing no benefitUltragenyx announced that its experimental therapy GTX-102 for Angelman syndrome did not demonstrate any benefit compared with a sham control in a large Phase 3 trial. The drug had previously show…
- Medline expands recall of reprocessed electrophysiology and ultrasound catheters due to contamination riskMedline Industries has issued an expanded recall that adds new lots of reprocessed electrophysiology and ultrasound catheters after the FDA identified possible residual particulates in the devices.…